Advances in Later-Lines of Therapy for GIST

Ripretinib will be evaluated in a phase 3 trial for patients with gastrointestinal stromal tumor after being added to the NCCN guidelines and receiving 2 breakthrough therapy designations from the FDA.

In season 3, episode 2 of Targeted Talks, Mark Agulnik, MD, discusses molecular testing for patients with sarcoma, treatment with targeted therapies, and ongoing research.

In the first article of this series, Moshe Ornstein, MD, a genitourinary medical oncologist at the Cleveland Clinic, gives an overview of renal cell carcinoma and discusses the treatment landscape.

In season 2, episode 10 of Targeted Talks, Sandra P. D'Angelo, MD, and Katherine Poruk, MD, discuss frontline treatment practices in the sarcoma space.

Brian Hill, MD, discusses the use of CAR T-cell therapy in earlier lines of treatment for mantle cell lymphoma and identifies other novel agents in this setting.

In an interview with Targeted Oncology, Everett E. Vokes, MD, discussed precision oncology for head and neck cancer and how the molecular biology of head and neck cancers is an opportunity for new investigations and treatment development.